An “alternative history” has revealed the potential impacts a smaller National Institutes of Health would have had on past ...

Known as a Section 232 investigation, the commerce department's work will cover everything from MRIs, robots and pacemakers to syringes, masks and gloves.

Sparrow Pharmaceuticals is looking to send its potential diabetes treatment soaring through clinical trials with the help of ...

Lantheus has inked a deal giving GE HealthCare the rights to carry its prostate cancer PET imaging agent in Japan, with the ...

While the average earnout potential per biopharma deal has declined over the last five years, the mean upfront value has been ...

Heartflow has secured a new FDA clearance for its artificial intelligence program to analyze the buildup of dangerous plaques ...

UniQure has set its sights on submitting its Huntington’s disease gene therapy for approval next year after the asset was ...

Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate ...

Glooko is looking to expand its diabetes treatment platforms to the inpatient setting, with a plan to acquire Monarch Medical ...

Sanofi is bestowing $625 million on its investment arm Sanofi Ventures, seeking to take advantage of a biotech landscape that ...

When it comes to Cyclerion Therapeutics' colorful backstory, the only consistency has been its inconsistency. | When it comes ...

Tuesday morning, Seres confirmed that one of these actions would involve reducing its workforce by 25%. Employees who are ...